Table 4 Adverse Events Reported as Reasons for Treatment Modifications in First-line Multikinase Inhibitor Treatment
Sunitinib | Sorafenib | |
|---|---|---|
(N = 85) | (N = 60) | |
At least one treatment modification due to AEs, n (%) | 34 (40.0) | 27 (45.0) |
Patients who discontinued first-line treatment due to AEs, n (%) | 10 (11.8) | 3 (5.0) |
Adverse Events a | ||
Anorexia | 4 (4.7) | 0 (0.0) |
Fatigue/asthenia | 3 (3.5) | 1 (1.7) |
Fever | 2 (2.4) | 0 (0.0) |
Dyspnea | 1 (1.2) | 1 (1.7) |
Abdominal pain | 1 (1.2) | 1 (1.7) |
Skin rash | 0 (0.0) | 1 (1.7) |
Patients with first-line treatment interruption due to AEs, n (%) | 20 (23.5) | 14 (23.3) |
Adverse Events a,b | ||
Fatigue/asthenia | 8 (9.4) | 2 (3.3) |
Diarrhea | 5 (5.9) | 4 (6.7) |
Hand-foot syndrome | 2 (2.4) | 3 (5.0) |
Vomiting | 5 (5.9) | 0 (0.0) |
Dyspnea | 2 (2.4) | 2 (3.3) |
Anemia | 2 (2.4) | 1 (1.7) |
Hypertension | 2 (2.4) | 1 (1.7) |
Skin rash | 0 (0.0) | 3 (5.0) |
Stomatitis/mucositis | 3 (3.5) | 0 (0.0) |
Gastritis | 2 (2.4) | 0 (0.0) |
Nausea | 2 (2.4) | 0 (0.0) |
Edema | 2 (2.4) | 0 (0.0) |
Ulcer | 2 (2.4) | 0 (0.0) |
Patients with first-line dose reduction due to AEs, n (%) | 26 (30.6) | 22 (36.7) |
Adverse Events a,b | ||
Fatigue/asthenia | 14 (16.5) | 12 (20.0) |
Hand-foot syndrome | 3 (3.5) | 11 (18.3) |
Diarrhea | 3 (3.5) | 7 (11.7) |
Stomatitis/mucositis | 4 (4.7) | 2 (3.3) |
Vomiting | 3 (3.5) | 1 (1.7) |
Dyspnea | 1 (1.2) | 2 (3.3) |
Hypertension | 1 (1.2) | 2 (3.3) |
Nausea | 3 (3.5) | 0 (0.0) |
Pain | 0 (0.0) | 2 (3.3) |
Stomach ache | 1 (1.2) | 2 (3.3) |
Hiccup | 2 (2.4) | 0 (0.0) |
Lack of appetite | 0 (0.0) | 2 (3.3) |
Edema | 2 (2.4) | 0 (0.0) |
Ulcer | 2 (2.4) | 0 (0.0) |